AR014456A1 - DERIVATIVES OF SULFONAMIDE AS INHIBITORS OF THE OSEA RESORTION AND AS INHIBITORS OF CELLULAR ADHESION, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM - Google Patents

DERIVATIVES OF SULFONAMIDE AS INHIBITORS OF THE OSEA RESORTION AND AS INHIBITORS OF CELLULAR ADHESION, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM

Info

Publication number
AR014456A1
AR014456A1 ARP990100244A ARP990100244A AR014456A1 AR 014456 A1 AR014456 A1 AR 014456A1 AR P990100244 A ARP990100244 A AR P990100244A AR P990100244 A ARP990100244 A AR P990100244A AR 014456 A1 AR014456 A1 AR 014456A1
Authority
AR
Argentina
Prior art keywords
alkyl
inhibitors
aryl
substituted
heteroaryl
Prior art date
Application number
ARP990100244A
Other languages
Spanish (es)
Original Assignee
Hoechst Marion Roussel Deutchland Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Deutchland Gmbh, Genentech Inc filed Critical Hoechst Marion Roussel Deutchland Gmbh
Publication of AR014456A1 publication Critical patent/AR014456A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se refiere a derivados de sulfonamida, que comprende un compuesto de la formula (I), donde: R1 y R2 independientemente son hidrogeno o alquilo (C1-6)que está no sustituido o sustituido por R3, o cuyos radicales R1 y R2 juntos son un radical alquileno (C2-9) saturado o no saturado, por ejemplo, el grupo-(CH2)p-, donde p es 1,2,3,4,5,6,7,8 o 9, que está no sustituido o sustituido por uno o más grupos formados por halogeno, alquilo (C1-6), alcoxi (C1-6),arilo (C1-14), aril-(C1-14)-alquilo-(C1-6), heteroarilo (C5-14), heteroaril-(C5-14)-alquilo-(C1-6), cicloalquilo-(C3-12),cicloalquil-(C3-12)-alquilo-(C1-6) y oxi, donde un anillo de cinco miembros a siete miembros saturado o no saturado no está sustituido o está sustituido porR3, y que es un anillo carbocíclico o un anillo heterocíclico que contiene uno o dos átomos de nitrogeno en el anillo, pueden fusionarse con un enlacecarbono-carbono en el radical alquileno-(C2-9); R3 es alquilo (C1-10), monocicloalquilo-(C3-20), bicicloalquilo-(C5-20), tricicloalquilo-(C5-20),alcoxi-(C1-8), arilo-(C6-14), aril-(C6-14)-alquilo-(C1-4)-, heteroarilo-(C5-14) heteroaril-(C5-14)-alquilo-(C1-4), halogeno, trifluorometilo, ciano, hidroxilo,oxo, nitro, amino, -NH-alquilo-(C1-4), -N(alquilo-(C1-4))2, -NH-CO-alquilo-(C1-4), -CO-alquilo-(C1-4); R4 es hidrogeno,alqui-(C1-6)-CO-O-alquilo-(C1-4) o alquilo-(C1-6) que está no sustituido o sustituido por un radical del grupo formado por hidroxilo,alcoxi-(C1-4),alquil-(C1-4)-S(O)2-, -NR7R7 y -N+R7R7R7Q-, donde R7, R7 y R7 independientemente uno del otro son hidrogeno, alquilo-(C1-6), arilo-(C5-14) oaril-(C5-14)-alquilo-(C1-6)- y Q- es un anion fisiologicamente tolerable, o dondeR4 es uno de los radicales, del grupo (II), en cuyos enlaces, por medioIt refers to sulfonamide derivatives, which comprises a compound of the formula (I), where: R1 and R2 independently are hydrogen or (C1-6) alkyl which is unsubstituted or substituted by R3, or whose radicals R1 and R2 together are a saturated or unsaturated (C2-9) alkylene radical, for example, the group- (CH2) p-, where p is 1,2,3,4,5,6,7,8 or 9, which is unsubstituted or substituted by one or more groups formed by halogen, (C1-6) alkyl, (C1-6) alkoxy, aryl (C1-14), aryl- (C1-14) -alkyl- (C1-6), heteroaryl ( C5-14), heteroaryl- (C5-14) -alkyl- (C1-6), cycloalkyl- (C3-12), cycloalkyl- (C3-12) -alkyl- (C1-6) and oxy, where a ring from five members to seven members saturated or unsaturated is not substituted or substituted by R3, and that is a carbocyclic ring or a heterocyclic ring containing one or two nitrogen atoms in the ring, they can be fused with a carbon-carbon bond in the radical alkylene- (C2-9); R3 is (C1-10) alkyl, monocycloalkyl- (C3-20), bicycloalkyl- (C5-20), tricycloalkyl- (C5-20), alkoxy- (C1-8), aryl- (C6-14), aryl - (C6-14) -alkyl- (C1-4) -, heteroaryl- (C5-14) heteroaryl- (C5-14) -alkyl- (C1-4), halogen, trifluoromethyl, cyano, hydroxyl, oxo, nitro , amino, -NH-alkyl- (C1-4), -N (alkyl- (C1-4)) 2, -NH-CO-alkyl- (C1-4), -CO-alkyl- (C1-4) ; R4 is hydrogen, alkyl- (C1-6) -CO-O-alkyl- (C1-4) or alkyl- (C1-6) which is unsubstituted or substituted by a radical of the group consisting of hydroxyl, alkoxy- (C1 -4), alkyl- (C1-4) -S (O) 2-, -NR7R7 and -N + R7R7R7Q-, where R7, R7 and R7 independently of each other are hydrogen, alkyl- (C1-6), aryl - (C5-14) oaryl- (C5-14) -alkyl- (C1-6) - and Q- is a physiologically tolerable anion, or where R4 is one of the radicals, of group (II), in whose bonds, by medium

ARP990100244A 1998-01-23 1999-01-29 DERIVATIVES OF SULFONAMIDE AS INHIBITORS OF THE OSEA RESORTION AND AS INHIBITORS OF CELLULAR ADHESION, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM AR014456A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1248998A 1998-01-23 1998-01-23

Publications (1)

Publication Number Publication Date
AR014456A1 true AR014456A1 (en) 2001-02-28

Family

ID=21755208

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100244A AR014456A1 (en) 1998-01-23 1999-01-29 DERIVATIVES OF SULFONAMIDE AS INHIBITORS OF THE OSEA RESORTION AND AS INHIBITORS OF CELLULAR ADHESION, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM

Country Status (25)

Country Link
EP (1) EP1049677A1 (en)
JP (1) JP2002501054A (en)
KR (1) KR20010034319A (en)
CN (1) CN1177832C (en)
AP (1) AP1269A (en)
AR (1) AR014456A1 (en)
AU (1) AU752882B2 (en)
BG (1) BG104630A (en)
BR (1) BR9907735A (en)
CA (1) CA2318221A1 (en)
EA (1) EA003102B1 (en)
HR (1) HRP20000493A2 (en)
HU (1) HUP0100520A3 (en)
ID (1) ID26219A (en)
IL (1) IL137423A0 (en)
NO (1) NO318795B1 (en)
NZ (1) NZ505613A (en)
PL (1) PL341871A1 (en)
SK (1) SK10632000A3 (en)
TR (1) TR200002160T2 (en)
TW (1) TWI247742B (en)
UA (1) UA63990C2 (en)
WO (1) WO1999037621A1 (en)
YU (1) YU47200A (en)
ZA (1) ZA99476B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100506A4 (en) * 1998-07-29 2002-06-26 Merck & Co Inc Integrin receptor antagonists
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1070707A1 (en) 1999-07-21 2001-01-24 Aventis Pharma Deutschland GmbH 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1108721A1 (en) * 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
AU2207001A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel compounds and process
FR2808798A1 (en) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease
FR2847254B1 (en) 2002-11-19 2005-01-28 Aventis Pharma Sa NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM
WO2005090329A1 (en) 2004-03-24 2005-09-29 Jerini Ag New compounds for the inhibition of angiogenesis and use of thereof
FR2870541B1 (en) 2004-05-18 2006-07-14 Proskelia Sas ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2873585B1 (en) * 2004-07-27 2006-11-17 Aventis Pharma Sa NEW GALENIC FORMULATIONS OF ACTIVE PRINCIPLES
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
US10005733B2 (en) 2014-12-17 2018-06-26 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0760658B1 (en) * 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption
JP3895792B2 (en) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス Bone formation promoter

Also Published As

Publication number Publication date
CA2318221A1 (en) 1999-07-29
NO318795B1 (en) 2005-05-09
EP1049677A1 (en) 2000-11-08
ID26219A (en) 2000-12-07
AU752882B2 (en) 2002-10-03
HUP0100520A1 (en) 2001-07-30
WO1999037621A1 (en) 1999-07-29
ZA99476B (en) 1999-08-05
BG104630A (en) 2001-04-30
AP2000001863A0 (en) 2000-09-30
YU47200A (en) 2002-11-15
TR200002160T2 (en) 2001-07-23
CN1177832C (en) 2004-12-01
AP1269A (en) 2004-04-03
AU2518199A (en) 1999-08-09
PL341871A1 (en) 2001-05-07
CN1293662A (en) 2001-05-02
NO20003765D0 (en) 2000-07-21
NO20003765L (en) 2000-09-25
EA003102B1 (en) 2002-12-26
HRP20000493A2 (en) 2001-06-30
KR20010034319A (en) 2001-04-25
NZ505613A (en) 2002-11-26
UA63990C2 (en) 2004-02-16
SK10632000A3 (en) 2001-02-12
JP2002501054A (en) 2002-01-15
HUP0100520A3 (en) 2002-11-28
EA200000785A1 (en) 2001-02-26
TWI247742B (en) 2006-01-21
IL137423A0 (en) 2001-07-24
BR9907735A (en) 2000-10-17

Similar Documents

Publication Publication Date Title
AR014456A1 (en) DERIVATIVES OF SULFONAMIDE AS INHIBITORS OF THE OSEA RESORTION AND AS INHIBITORS OF CELLULAR ADHESION, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
AR016437A1 (en) ACILGUANIDINE DERIVATIVES AS OSEA RESORTION INHIBITORS AND AS VITRONECTINE RECEIVER ANTAGONISTS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL PREPARATION THAT INCLUDE THEM
AR021434A1 (en) BENZAMIDA THERAPEUTIC DERIVATIVES
AR018358A1 (en) TIENIL-REPLACED ACILGUANIDINS AS INHIBITORS OF BONE RESORTION AND AS ANTAGONISTS OF VITRONECTINE RECEPTORS, A PARASU PREPARATION AND PHARMACEUTICAL COMPOSITION PROCESS THAT INCLUDES THEM
AR042583A1 (en) MACROLIDOS
AR011174A1 (en) PIRAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE IN THE PEPARATION OF MEDICINES AND THE PROCESS TO PREPARE THEM
PE20021010A1 (en) SPIROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE-7 INHIBITORS
UY23840A1 (en) PROCEDURE FOR THE PREPARATION OF HIV PROTEASE INHIBITORS
AR048315A1 (en) INHIBITING HETEROCICLICAL COMPOUNDS OF CITOCINE PRODUCTION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF INFLAMMATORY AND ONCOLOGICAL DISEASES.
AR082231A2 (en) PIRIDINES AND PIRIDAZINAS REPLACED WITH ANGIOGENESIS INHIBITION ACTIVITY, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR023703A1 (en) N-CARBONYLOXIMETHYLTERS OF NITROETILENDIAMINS AND NITROGUANIDINS, PROCESS FOR PREPARATION, PARASITICIATED COMPOSITION, A PREPARATION IN COMBINATION TO CONTROL PARASITES IN HOT BLOOD ANIMALS, USE OF SUCH COMPOSITES FOR USE
AR045938A1 (en) ACTIVE MACROCICLIC PEPTIDES AGAINST HEPATITIS C VIRUS
PE20080704A1 (en) INDOLOBENZAZEPINE HEPATITIS C VIRUS INHIBITORS NS5B FUSED TO CYCLOPROPYL
AR029301A1 (en) COMPOUNDS DERIVED FROM BIARILO, METHODS FOR THEIR PREPARATION COMPOSITIONS THAT CONTAIN THEM, THEIR USE AS AGONISTS IN BETA-ADRENO-ATIPIC RECEIVERS
AR051698A1 (en) PIRROLO DERIVATIVES [3,2-D] PIRIMIDIN-4-ONA AS MYELOPEROXIDASE INHIBITORS
AR022848A1 (en) IMIDAZOL COMPOUNDS REPLACED WITH A SIX OR SEVEN MEMBER HETEROCICLIC RING CONTAINING TWO NITROGEN ATOMS
PE20000048A1 (en) ASPARTIL PROTEASE INHIBITORS PRODROGS
AR006720A1 (en) A COMPOUND DERIVED FROM HETERO-CYCLIC AZAHEXANE, ITS USE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, PROCEDURE FOR PREPARING IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
AR039189A1 (en) PIRROLOPIRIDAZINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION
PE20011066A1 (en) PYRID [2,3-d] PYRIMIDIN-2,7-DIAMINES KINE INHIBITORS
ES2059335T3 (en) DERIVATIVES OF PIRIDO (3,2,1-IJ) -1,3,4-BENZOXADIAZINA, PROCEDURE FOR ITS OBTAINING, CORRESPONDING PHARMACEUTICAL PREPARATIONS AND INTERMEDIATE PRODUCTS USABLE IN THE PROCEDURE.
MX23949A (en) DIAZA COMPOUNDS, AND PROCEDURE FOR ITS PREPARATION AND ANTI-HYPERTESSIVE PHARMACEUTICAL COMPOCITIONS FOR THE TREATMENT OF CARDIAC DISEASES THAT INCLUDE THEM.
ES2179005T3 (en) CHROMENE COMPOUND
ES2072108T3 (en) STAINING PROCEDURE OF KERATINIC FIBERS ASSOCIATED BY ISATIN OR ONE OF ITS DERIVATIVES TO AN AMINOPYRIDINE OR AMINOPYRIMIDINE, AND STAINING AGENTS.
AR030203A1 (en) CARBAMATE DERIVATIVES OF 2- (S) -HYDROXIMUTILINE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, PROCEDURE TO PREPARE THEM AND 2 (S), 11-PROTECTED-MUTILINE DIHYDROXY AS A INTERMEDIARY COMPOUND

Legal Events

Date Code Title Description
FA Abandonment or withdrawal